PL3788045T3 - Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania - Google Patents

Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania

Info

Publication number
PL3788045T3
PL3788045T3 PL19724662.2T PL19724662T PL3788045T3 PL 3788045 T3 PL3788045 T3 PL 3788045T3 PL 19724662 T PL19724662 T PL 19724662T PL 3788045 T3 PL3788045 T3 PL 3788045T3
Authority
PL
Poland
Prior art keywords
making
methods
same
inhibitory compounds
rip1
Prior art date
Application number
PL19724662.2T
Other languages
English (en)
Inventor
Ihab Darwish
Jiaxin Yu
Yan Chen
Esteban Masuda
Vanessa Taylor
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of PL3788045T3 publication Critical patent/PL3788045T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL19724662.2T 2018-05-03 2019-05-02 Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania PL3788045T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666452P 2018-05-03 2018-05-03
PCT/US2019/030473 WO2019213445A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (1)

Publication Number Publication Date
PL3788045T3 true PL3788045T3 (pl) 2023-10-09

Family

ID=66554488

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19724662.2T PL3788045T3 (pl) 2018-05-03 2019-05-02 Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania

Country Status (38)

Country Link
US (3) US10975064B2 (pl)
EP (1) EP3788045B1 (pl)
JP (1) JP7379467B2 (pl)
KR (1) KR102823195B1 (pl)
CN (1) CN112384510B (pl)
AU (1) AU2019262142B2 (pl)
BR (1) BR112020022423A2 (pl)
CA (1) CA3099018A1 (pl)
CL (1) CL2020002840A1 (pl)
CO (1) CO2020015153A2 (pl)
CR (1) CR20200582A (pl)
CY (1) CY1126152T1 (pl)
DK (1) DK3788045T3 (pl)
DO (1) DOP2020000197A (pl)
EA (1) EA202092581A1 (pl)
EC (1) ECSP20077518A (pl)
ES (1) ES2947446T3 (pl)
FI (1) FI3788045T3 (pl)
HR (1) HRP20230909T1 (pl)
HU (1) HUE062277T2 (pl)
IL (1) IL278416B2 (pl)
JO (1) JOP20200277A1 (pl)
LT (1) LT3788045T (pl)
MA (1) MA52492B1 (pl)
MD (1) MD3788045T2 (pl)
MX (1) MX2020011622A (pl)
MY (1) MY205388A (pl)
PE (1) PE20210414A1 (pl)
PH (1) PH12020551848A1 (pl)
PL (1) PL3788045T3 (pl)
PT (1) PT3788045T (pl)
RS (1) RS64418B1 (pl)
SG (1) SG11202010913PA (pl)
SI (1) SI3788045T1 (pl)
SM (1) SMT202300203T1 (pl)
UA (1) UA128160C2 (pl)
WO (1) WO2019213445A1 (pl)
ZA (1) ZA202007487B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3788044T2 (ro) 2018-05-03 2023-12-31 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
EA202092581A1 (ru) 2018-05-03 2021-04-08 Ригел Фармасьютикалз, Инк. Соединения, ингибирующие rip1, а также способы их получения и применения
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
BR112022002581A2 (pt) * 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Inibidores heterocíclicos de rip1 quinase
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020378407B2 (en) * 2019-11-07 2024-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
CN114981248A (zh) * 2019-11-26 2022-08-30 德州大学系统董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
AR121717A1 (es) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
TW202227447A (zh) * 2020-08-18 2022-07-16 大陸商和記黃埔醫藥(上海)有限公司 嘧啶酮類化合物及其用途
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
TW202311261A (zh) * 2021-05-14 2023-03-16 大陸商中國醫藥研究開發中心有限公司 氮呯類稠環化合物及其醫藥用途
CN115894489A (zh) * 2021-09-22 2023-04-04 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF
KR20230100646A (ko) * 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP5645663B2 (ja) 2007-08-15 2014-12-24 プレジデント アンド フェローズ オブ ハーバード カレッジ ネクロトーシスのヘテロ環式抑制剤
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
US20170266199A1 (en) * 2014-08-21 2017-09-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2016128936A1 (en) 2015-02-13 2016-08-18 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
PE20180501A1 (es) 2015-07-02 2018-03-09 Hoffmann La Roche Lactamas biciclicas y metodos de uso de las mismas
WO2017064217A1 (en) 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
AU2016340527B2 (en) 2015-10-23 2020-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
JP6974331B2 (ja) 2016-02-05 2021-12-01 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 化合物、組成物及び方法
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
MD3788044T2 (ro) 2018-05-03 2023-12-31 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
EA202092581A1 (ru) * 2018-05-03 2021-04-08 Ригел Фармасьютикалз, Инк. Соединения, ингибирующие rip1, а также способы их получения и применения
EP3816163A4 (en) 2018-06-26 2022-04-13 Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences CELLULAR NECROSIS INHIBITOR, METHOD FOR PREPARATION AND USE
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
BR112022002581A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Inibidores heterocíclicos de rip1 quinase
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
AU2020378407B2 (en) * 2019-11-07 2024-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
IL278416B2 (en) 2023-12-01
US10975064B2 (en) 2021-04-13
HRP20230909T1 (hr) 2023-12-08
MA52492B1 (fr) 2023-09-27
MD3788045T2 (ro) 2023-09-30
MX2020011622A (es) 2021-02-17
KR102823195B1 (ko) 2025-06-20
US20190337934A1 (en) 2019-11-07
US11919890B2 (en) 2024-03-05
PE20210414A1 (es) 2021-03-04
PT3788045T (pt) 2023-06-26
SMT202300203T1 (it) 2023-09-06
PH12020551848A1 (en) 2021-06-28
CY1126152T1 (el) 2023-11-15
AU2019262142A1 (en) 2020-11-26
UA128160C2 (uk) 2024-04-24
WO2019213445A1 (en) 2019-11-07
US20210214347A1 (en) 2021-07-15
IL278416B1 (en) 2023-08-01
EA202092581A1 (ru) 2021-04-08
CR20200582A (es) 2021-04-14
IL278416A (pl) 2020-12-31
AU2019262142B2 (en) 2024-11-21
CN112384510A (zh) 2021-02-19
CL2020002840A1 (es) 2021-04-16
CO2020015153A2 (es) 2021-03-08
HUE062277T2 (hu) 2023-10-28
KR20210006407A (ko) 2021-01-18
SI3788045T1 (sl) 2023-07-31
SG11202010913PA (en) 2020-12-30
FI3788045T3 (fi) 2023-06-28
ES2947446T3 (es) 2023-08-09
EP3788045A1 (en) 2021-03-10
ECSP20077518A (es) 2021-03-31
LT3788045T (lt) 2023-06-26
EP3788045B1 (en) 2023-05-31
CN112384510B (zh) 2025-06-13
MA52492A (fr) 2021-03-10
JP7379467B2 (ja) 2023-11-14
ZA202007487B (en) 2023-01-25
MY205388A (en) 2024-10-19
DOP2020000197A (es) 2021-04-30
US20240217958A1 (en) 2024-07-04
RS64418B1 (sr) 2023-09-29
DK3788045T3 (da) 2023-06-26
BR112020022423A2 (pt) 2021-02-02
CA3099018A1 (en) 2019-11-07
JP2021523225A (ja) 2021-09-02
JOP20200277A1 (ar) 2020-11-03

Similar Documents

Publication Publication Date Title
ZA202108603B (en) Rip1 inhibitory compounds and methods for making and using the same
IL291033A (en) rip1 inhibitory compounds and methods for their preparation and use
ZA202007487B (en) Rip1 inhibitory compounds and methods for making and using the same
IL290781A (en) rip1 inhibitory compounds and methods for their preparation and use
IL277502A (en) Compounds and uses for them
PL3594199T3 (pl) Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
SG11202009175RA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
SG11202009138QA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
EP3899293C0 (en) LOCK NUT
EP3724933A4 (en) SUPRAL CONDUCTING COMPOUNDS AND METHOD FOR PRODUCING THEREOF
IL279483A (en) Cyanotriazole compounds and their uses
IL283309A (en) rip1 inhibitors
EP3743635A4 (en) ANTI-KICKBACK LOCK
HK40091929A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40067714A (en) Rip1 inhibitory compounds and methods for making and using the same
GB201917427D0 (en) The flylead
GB201916822D0 (en) The degravitator
ZA201906782B (en) Mulcher
HK40043702A (en) Cyanotriazole compounds and uses thereof
GB201904750D0 (en) The dehydrometer
HK40040535A (en) Superconducting compounds and methods for making the same
HK40046944A (en) Pladienolide compounds and their use
GB201902293D0 (en) The hangit
GB201808686D0 (en) The dogtooth
AU2018903548A0 (en) Substituted-pyridinyl compounds and uses thereof